Tim Loh

Sanofi’s Dupixent has been cleared for a chronic lung disorder in the US, in another milestone for the blockbuster drug after a similar decision by European regulators.

Sanofi's Dupixent has been cleared for a chronic lung disorder in the US, in another milestone for the blockbuster drug after a similar decision by European regulators.

Sanofi's Dupixent has been cleared for a chronic lung disorder in the US, in another milestone for the blockbuster drug after a similar decision by European regulators.

Adidas AG raised its annual profit target for the third quarter in a row amid the sustained boom for retro sneakers like the Samba and more sales from its shrinking stockpile of Yeezy footwear.

Sanofi’s Dupixent has been cleared for a chronic lung disorder in the US, in another milestone for the blockbuster drug after a similar decision by European regulators.

Sanofi’s profit rose on demand for its flu vaccines and a shot for a common respiratory virus, as well as further growth in its blockbuster skin and asthma therapy Dupixent.

Earnings per share excluding some items reached €2.86 ($3.10) in the third quarter, exceeding analysts’ estimates.

(Bloomberg) -- Sanofi profit rose on demand for seasonal vaccines and further growth in its blockbuster skin and asthma therapy Dupixent.

Bayer AG cut its profit outlook for the year on stubbornly low prices for agriculture products, including the controversial weedkiller Roundup.

Federer-backed company quarterly sales beat estimates Executive says running is among fastest-growing categories